Jeffrey Del Carmen compensation by year
CATALYST PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $449,000 | $475,000 | $525,000 | $546,000 |
| Bonus | $211,200 | $256,500 | $275,625 | $327,600 |
| Stock awards | $725,900 | $341,256 | $355,006 | $734,492 |
| Option awards | $948,830 | $1,364,991 | $1,420,124 | $1,101,807 |
| Non-equity incentive | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $51,502 | $68,319 | $62,372 | $74,648 |
| Total | $2,386,432 | $2,506,066 | $2,638,127 | $2,784,547 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CATALYST PHARMACEUTICALS, INC. 10-K/A filed April 30, 2026, accession 0001193125-26-197490, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CATALYST PHARMACEUTICALS, INC. filed document, accession 0001193125-26-197490. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 32,257 | $0 | — |
| PSU | 11,206 | $0 | — |
| PSU | 8,039 | $0 | — |
| Option | 106,873 | — | $22.77 |
| Option | 91,702 | — | $21.12 |
| Option | 55,973 | — | $14.15 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CATALYST PHARMACEUTICALS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
11 Form 4 lines since the FY2024 proxy (filed April 30, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-15 | Disposition to the issuer derivative | — | 88,000 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 11,206 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 32,257 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer | — | 14,337 | $31.50 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 135,000 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 137,553 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 106,873 | $0.00 | 0 |
| 2026-07-15 | Disposition to the issuer derivative | — | 150,000 | $0.00 | 0 |
The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments CATALYST PHARMACEUTICALS discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Retirement | $0 | $0 | $0 | $0 |
| Resignation for good reason, no change in control | $525,000 | — | — | $525,000 |
| Death | $0 | $0 | $0 | $0 |
| Disability | $0 | $0 | $0 | $0 |
| Change in control and involuntary termination | $525,000 | — | — | $525,000 |
| Involuntary termination without cause | $525,000 | — | — | $525,000 |
| Involuntary for cause | $0 | $0 | $0 | $0 |
| Voluntary resignation | $0 | $0 | $0 | $0 |
Per the Potential Payments Upon Termination or Change in Control table in CATALYST PHARMACEUTICALS, INC.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
CATALYST PHARMACEUTICALS’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Richard Daly | President and CEO | $7,774,160 |
| Michael Kalb | EVP and CFO | $6,180,936 |
| Steven Miller | COO and CSO | $3,545,774 |
| Jeffrey Del Carmen · this page | CCO | $2,638,127 |
| Preethi Sundaram | Chief Strategy Officer | $2,528,555 |
Jeffrey Del Carmen's compensation dossier, CATALYST PHARMACEUTICALS
You have read Jeffrey Del Carmen's totals and holdings. The dossier adds each equity grant CATALYST PHARMACEUTICALS disclosed for Jeffrey Del Carmen and CATALYST PHARMACEUTICALS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full CATALYST PHARMACEUTICALS compensation record
free company briefThis page is one person within CATALYST PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the CATALYST PHARMACEUTICALS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CATALYST PHARMACEUTICALS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CATALYST PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CPRX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.